3-Isoquinolinecarboxamide, 2-[(2S,3S)-2-[(3,3-dimethyl-1-oxobutyl)amino]-3-methyl-1-oxopentyl]-1,2,3,4-tetrahydro-7-[2-(hydroxyamino)-2-oxoethoxy]-N-(4-methoxyphenyl)-, (3S)- manufacturers
- ZYJ-34c
-
- $1670.00
-
2026-05-11
- CAS:1314556-93-8
- Purity:
- Supply Ability: 10g
|
| | 3-Isoquinolinecarboxamide, 2-[(2S,3S)-2-[(3,3-dimethyl-1-oxobutyl)amino]-3-methyl-1-oxopentyl]-1,2,3,4-tetrahydro-7-[2-(hydroxyamino)-2-oxoethoxy]-N-(4-methoxyphenyl)-, (3S)- Basic information |
| Product Name: | 3-Isoquinolinecarboxamide, 2-[(2S,3S)-2-[(3,3-dimethyl-1-oxobutyl)amino]-3-methyl-1-oxopentyl]-1,2,3,4-tetrahydro-7-[2-(hydroxyamino)-2-oxoethoxy]-N-(4-methoxyphenyl)-, (3S)- | | Synonyms: | 3-Isoquinolinecarboxamide, 2-[(2S,3S)-2-[(3,3-dimethyl-1-oxobutyl)amino]-3-methyl-1-oxopentyl]-1,2,3,4-tetrahydro-7-[2-(hydroxyamino)-2-oxoethoxy]-N-(4-methoxyphenyl)-, (3S)-;ZYJ 34c;ZYJ34c;ZYJ-34c | | CAS: | 1314556-93-8 | | MF: | C31H42N4O7 | | MW: | 582.69 | | EINECS: | | | Product Categories: | | | Mol File: | 1314556-93-8.mol | ![3-Isoquinolinecarboxamide, 2-[(2S,3S)-2-[(3,3-dimethyl-1-oxobutyl)amino]-3-methyl-1-oxopentyl]-1,2,3,4-tetrahydro-7-[2-(hydroxyamino)-2-oxoethoxy]-N-(4-methoxyphenyl)-, (3S)- Structure](CAS/20210305/GIF/1314556-93-8.gif) |
| | 3-Isoquinolinecarboxamide, 2-[(2S,3S)-2-[(3,3-dimethyl-1-oxobutyl)amino]-3-methyl-1-oxopentyl]-1,2,3,4-tetrahydro-7-[2-(hydroxyamino)-2-oxoethoxy]-N-(4-methoxyphenyl)-, (3S)- Chemical Properties |
| density | 1+-.0.06 g/cm3(Predicted) | | pka | 9.13±0.20(Predicted) |
| | 3-Isoquinolinecarboxamide, 2-[(2S,3S)-2-[(3,3-dimethyl-1-oxobutyl)amino]-3-methyl-1-oxopentyl]-1,2,3,4-tetrahydro-7-[2-(hydroxyamino)-2-oxoethoxy]-N-(4-methoxyphenyl)-, (3S)- Usage And Synthesis |
| Description | ZYJ-34c is a histone deacetylase inhibitor (HDACi) with potent oral antitumor activities. | | Uses | ZYJ-34c is an orally active and potent histone deacetylase inhibitor (HDACi) with IC50s of 0.056 μM and 0.146 μM for HDAC6 and HDAC8, respectively. ZYJ-34c causes G1 phase arrest in low concentration. ZYJ-34c has antiproliferative activities. ZYJ-34c exhibits antitumor potency in MDA-MB-231 and HCT116 xenograft models and possesses antimetastatic potential in a mouse hepatoma-22 (H22) pulmonary metastasis model[1]. | | IC 50 | HDAC6: 0.056 μM (IC50); HDAC8: 0.146 μM (IC50) | | References | [1] Yingjie Zhang, et al. Discovery of a tetrahydroisoquinoline-based hydroxamic acid derivative (ZYJ-34c) as histone deacetylase inhibitor with potent oral antitumor activities. J Med Chem. 2011 Aug 11;54(15):5532-9. DOI:10.1021/jm200577a |
| | 3-Isoquinolinecarboxamide, 2-[(2S,3S)-2-[(3,3-dimethyl-1-oxobutyl)amino]-3-methyl-1-oxopentyl]-1,2,3,4-tetrahydro-7-[2-(hydroxyamino)-2-oxoethoxy]-N-(4-methoxyphenyl)-, (3S)- Preparation Products And Raw materials |
|